| Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. | |
| | |
MedLine Citation:
|
PMID: 18846987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Guidelines for the management of hypertension almost invariably include sections where the evidence for or against treatment or for certain types of treatment in certain types of patients is inconclusive. This is especially the case of older patients with hypertension. As a consequence, although a large number of randomized trials including hypertensive patients aged > or = 60 years showed that antihypertensive drugs reduce cardiovascular morbidity and mortality, health care professionals who take care of older adults have been often reluctant to provide adequate antihypertensive therapy. In a recent meta-analysis, the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) compared the effects of different drugs for reducing blood pressure (BP) in older and younger adults; the reduction in BP levels and the relative risk reduction of a cardiovascular event with various antihypertensive drugs occurred independently of the patients' ages, and the benefits of antihypertensive regimens based on different drug classes were widely comparable across age groups. The BPLTTC analysis strongly suggests an early and aggressive management of hypertension irrespectively of age; more myocardial infarctions, strokes, heart failures and deaths will be prevented by treating hypertensive patients aged > or = 65 years than by treating patients < or = 50 years with the same BP levels. Antihypertensive treatment should be embedded within the management of global cardiovascular risk, with the use of charts for stratifying risk based on additional risk factors, target organ damage or additional clinical conditions. |
| | |
Authors:
|
Paolo Verdecchia; Giorgio Gentile; Fabio Angeli; Gianpaolo Reboldi |
Related Documents
:
|
2510057 - Hypertension in primary glomerulonephritis without renal insufficiency. 15972577 - Primary empty sella. 17903257 - Frequency of complementary and alternative medicine utilization in hypertensive patient... 12904327 - Obstructive sleep apnea and thoracic aorta dissection. 3389247 - Clinical prognostic indices of fatality in elderly patients admitted to hospital with a... 1910467 - Positioning and immobilization of patients undergoing radiation therapy for hodgkin's d... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Polskie Archiwum Medycyny Wewn?trznej Volume: 118 ISSN: 0032-3772 ISO Abbreviation: Pol. Arch. Med. Wewn. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-13 Completed Date: 2009-01-14 Revised Date: 2010-04-01 |
Medline Journal Info:
|
Nlm Unique ID: 0401225 Medline TA: Pol Arch Med Wewn Country: Poland |
Other Details:
|
Languages: eng Pagination: 513-6 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Clinical Research Unit "Preventive Cardiology" Hospital "Santa Maria della Misericordia", Perugia, Italy. verdec@tin.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers / pharmacology, therapeutic use* Angiotensin-Converting Enzyme Inhibitors / pharmacology, therapeutic use* Antihypertensive Agents / pharmacology, therapeutic use* Blood Pressure / drug effects Calcium Channel Blockers / pharmacology, therapeutic use* Europe Heart Failure / prevention & control Humans Hypertension / drug therapy* Meta-Analysis as Topic Poland Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Calcium Channel Blockers |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Should we prefer different drugs to treat hypertension in older and younger adults? Practical implic...
Next Document: Myocardial infarction in a 30-year-old patient with pheochromocytoma and type 1 neurofibromatosis.